| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.8 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | 0.0093 | 0.8 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | -0.0081 | 0.8 |
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | -0.0093 | 0.8 |
| mRNA | MS-275 | GDSC1000 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | -0.0087 | 0.8 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.8 |
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | -0.047 | 0.8 |
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.8 |